William Allan Corp Acquires 383 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

William Allan Corp increased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 5.5% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 7,383 shares of the medical instruments supplier’s stock after buying an additional 383 shares during the quarter. West Pharmaceutical Services comprises approximately 1.5% of William Allan Corp’s portfolio, making the stock its 28th biggest position. William Allan Corp’s holdings in West Pharmaceutical Services were worth $2,418,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Northwest Investment Counselors LLC bought a new stake in West Pharmaceutical Services in the 3rd quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new position in West Pharmaceutical Services in the fourth quarter worth about $34,000. Brooklyn Investment Group purchased a new position in West Pharmaceutical Services in the third quarter worth about $41,000. MassMutual Private Wealth & Trust FSB boosted its position in West Pharmaceutical Services by 60.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 209 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 79 shares during the last quarter. Finally, Hilltop National Bank boosted its position in West Pharmaceutical Services by 47.9% in the fourth quarter. Hilltop National Bank now owns 216 shares of the medical instruments supplier’s stock worth $71,000 after purchasing an additional 70 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

WST has been the topic of a number of analyst reports. UBS Group raised West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $350.00 to $390.00 in a research report on Thursday, December 12th. StockNews.com raised West Pharmaceutical Services from a “hold” rating to a “buy” rating in a report on Friday, January 31st. Bank of America lifted their price objective on West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Citigroup began coverage on West Pharmaceutical Services in a research note on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price objective on the stock. Finally, Wolfe Research began coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $430.20.

West Pharmaceutical Services Stock Performance

NYSE WST opened at $330.53 on Friday. The company has a market cap of $23.94 billion, a P/E ratio of 49.04, a P/E/G ratio of 19.82 and a beta of 1.01. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.23 and a current ratio of 3.00. The business’s 50 day moving average price is $332.39 and its 200-day moving average price is $314.53. West Pharmaceutical Services, Inc. has a fifty-two week low of $265.00 and a fifty-two week high of $413.70.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 11th. Shareholders of record on Friday, February 7th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.25%. The ex-dividend date is Friday, February 7th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 12.46%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.